With Cortado Ventures initial investment, Moat Biotechnology Raises $6.5M in First Close for Intranasal/Inhaled Covid-19 Vaccine

Oklahoma City — Touted as “the first U.S.-based company with promising proof of concept for intranasal/inhaled adenovirus vaccines, Moat Biotechnology Corporation (MoatBio), announces it has raised more than $6.5 million

Related Keywords

Australia ,Scott Rollins ,Russell Rother ,Mike Moradi ,Selexys Pharmaceuticals ,Novartis ,Tetherex Pharmaceuticals ,Moat Biotechnology Corporation Moatbio ,Astrazeneca ,Alexion Pharmaceuticals ,Drug Development ,Oklahoma City ,Moat Biotechnology Corporation ,Mayo Clinic ,Cortado Ventures ,Boyd Street Ventures ,Executive Vice President ,Chief Scientific Officer ,General Partner ,Business ,Energy ,Health ,